Status:
RECRUITING
Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis
Lead Sponsor:
University Hospital, Bordeaux
Collaborating Sponsors:
Ministry for Health and Solidarity, France
Conditions:
Thrombocytopenia
Immune Thrombocytopenia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Immune thrombocytopenia (ITP) is an autoimmune disease but, paradoxically, and unlike other autoimmune diseases, antiplatelet antibodies are not used either for the diagnosis of the disease or for its...
Eligibility Criteria
Inclusion
- Patient over 18 years old;
- Patients with thrombocytopenia \<100 G/L, checked twice, having ruled out false thrombocytopenia by platelet aggregation and acute leukemia by smear;
- No treatment started;
- Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and prior to any review required by the research);
- Person affiliated or benefiting from a social security scheme.
Exclusion
- Secondary ITP;
- False thrombocytopenia;
- Patients who have been transfused with platelets for less than 7 days with efficacy;
- Patient treated for thrombocytopenia (48 hours of corticosteroid therapy is tolerated and is not an exclusion criteria);
- Patient with acute leukemia;
- Pregnant or breastfeeding woman;
- False thrombocytopenia;
- Patient under guardianship, curatorship or any other legal protection regime.
Key Trial Info
Start Date :
May 19 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2027
Estimated Enrollment :
225 Patients enrolled
Trial Details
Trial ID
NCT04800458
Start Date
May 19 2021
End Date
May 1 2027
Last Update
June 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Bordeaux - service de médecine interne
Pessac, France